Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Carboplatin and Pemetrexed in Recurrent Platinum Sensitive Ovarian Cancer

This study has been completed.
Massachusetts General Hospital
Brigham and Women's Hospital
Information provided by (Responsible Party):
Ursula A. Matulonis, MD, Dana-Farber Cancer Institute Identifier:
First received: September 29, 2005
Last updated: March 29, 2016
Last verified: January 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: April 2011
  Primary Completion Date: July 2007 (Final data collection date for primary outcome measure)